Dr. Andre Goy on Future Treatments for Patients With Diffuse Large B-Cell Lymphoma

November 18, 2015
Andre Goy, MD, MS

Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, MS, chief, John Theurer Cancer Center’s Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

Goy says that some of the upcoming novel agents showing promise are bortezomib, both as a single agent and in conjunction with R-CHOP chemotherapy, as well as ibrutinib. Both ibrutinib and bortezomib showed great promise in phase II clinical trials and will be going on to phase III trials to determine their viability as treatments.